Shanghai CP Guojian Pharmaceutical Co.,Ltd.   Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4
Founded: Shanghai China (1998)

Organization Overview

First Clinical Trial
2005
NCT01439191
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (2)

etanercept (enbrel) (1 trial)

naltrexone (revia) (1 trial)

Drugs in Phase 3 Trials (6)

Key: Shanghai CP Guojian Pharmaceutical Co.,Ltd. (5) Acquired (1)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (3)

Key: Shanghai CP Guojian Pharmaceutical Co.,Ltd. (2) Acquired (1)

epoetin (Epogen) (2 trials)

trastuzumab (herceptin) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 1 Trials (1)

Key: Shanghai CP Guojian Pharmaceutical Co.,Ltd. (0) Acquired (1)

tbi 302 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Lymphoma (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Psoriasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 12